Understanding the Potential Impact of GLP-1 Medications on Bone Health

GLP-1 agonists, such as Ozempic, Wegovy, and Zepbound, have significantly changed the landscape of treatments for obesity, type 2 diabetes, and other chronic health conditions, positively impacting millions of Americans. However, like any medication, they can have side effects. A recent study presented at the 2026 American Academy of Orthopaedic Surgeons annual meeting suggests a potential link between GLP-1 use and risks related to bone health, specifically osteoporosis and gout.

The research analyzed five years of medical records from nearly 147,000 adults diagnosed with both obesity and type 2 diabetes. Authors reported an association between GLP-1 use and an increased risk of osteoporosis, osteomalacia (soft bones), and gout, a form of arthritis marked by joint pain and swelling. This stirred concern among patients and healthcare providers alike.

Are the Findings Cause for Concern?

While the findings raise questions, experts caution against jumping to conclusions. Dr. Marci Laudenslager, an obesity medicine physician at Johns Hopkins, emphasizes that there is currently no solid scientific evidence indicating that GLP-1s directly lead to osteoporosis or osteomalacia. Similarly, she notes that the association with gout is primarily hypothetical at this stage.

The study's observational nature implies it noted correlations without proving direct cause-and-effect relationships. Observational studies can suggest potential associations, but they are not definitive regarding medication effects. Moreover, the reliance on medical records presents limitations; adherence to prescribed treatments may vary significantly among individuals. Many patients can't afford GLP-1s or may face supply issues, affecting actual medication usage. Therefore, the patients included in the study might not accurately reflect those who are consistently taking the medication.

Another limitation involved factors affecting bone health that weren't fully addressed in the study, such as exercise habits, nutritional choices, and other lifestyle influences that hold considerable sway over bone integrity. Additionally, certain medical conditions, like endocrine disorders or alcohol use, which can impact bone health, were not explored in detail. The lack of specifics on the GLP-1 drugs involved and their dosages also complicates interpretations of the results. The study's findings await peer review, a crucial step in validating research claims.

Link Between GLP-1 Use and Bone Health

Despite the limitations of the aforementioned study, other research indicates that GLP-1 medications could potentially affect bone density, though this connection appears indirect. Both Dr. Laudenslager and Kelyssa Hall, an exercise physiologist, concur that weight loss associated with GLP-1 usage could contribute to decreased bone density. This is primarily attributed to the rapid weight loss experienced by some patients.

According to Hall, “When you take GLP-1s, there can be rapid weight loss, meaning there is less load on the skeleton.” Bone strength and formation benefit from physical load, so a reduction in weight may inadvertently lead to decreased bone density. Dr. Laudenslager echoes this point, stating that weight loss from any means—whether through lifestyle changes, medications, or surgery—can significantly influence overall metabolism, including that of bones. Importantly, this is not an adverse effect specifically linked to GLP-1s but rather a general concern for rapid weight loss.

Thus, although some users report changes in bone health while using GLP-1 medications, it appears that these changes are largely driven by the extent of weight loss rather than a direct negative effect of the drugs themselves. Bone health in relation to GLP-1 usage remains an evolving area of research, necessitating further studies to clarify these relationships.

Protecting Your Bone Health While Taking GLP-1s

If you're using GLP-1 medications, there are practical strategies you can adopt to help safeguard your bone health:

1. Incorporate Strength Training

Strength training is beneficial for everyone, but especially for those using GLP-1s. It has been shown to enhance bone density, making it a vital component of a healthy routine. Importantly, it can also counteract muscle loss that sometimes accompanies weight loss. Dr. Laudenslager recommends gradually building a regimen of two to three strength-training sessions a week, ensuring rest days to allow muscle recovery. Always consult your doctor before starting a new exercise program.

2. Ensure Sufficient Caloric Intake

Appetite suppression is a common effect of GLP-1s, which can lead to unintentional calorie deficits. Not consuming enough calories may negatively affect bone health and overall well-being. Dr. Laudenslager urges individuals to consider their caloric needs and discuss dietary sufficiency with their healthcare provider or a registered dietitian. Maintaining adequate nutrition is crucial for sustaining health during weight loss.

3. Focus on Protein Intake

Protein is essential for muscle building and also plays a significant role in bone health. The general recommendation for adults is 0.8 grams of protein per kilogram of body weight daily. Dr. Laudenslager suggests that individuals at higher risk for bone issues may need slightly more protein. However, be mindful to consume a variety of nutrients essential for a balanced diet, including healthy fats and vitamins.

4. Aim for Gradual Weight Loss

Rapid weight loss can be problematic for bone health. Experts propose a gradual weight loss strategy, around 5% to 10% of total body weight within six months, which roughly translates to losing about 0.5 to 2 pounds weekly. If you notice significant weight loss while on GLP-1s, it’s worth discussing with your healthcare provider. They may adjust your dosage to facilitate a healthy rate of weight loss.

5. Discuss Any Concerns with Your Doctor

Bone health changes often occur slowly over time. The potential for significant bone loss generally unfolds over several years, providing multiple opportunities to monitor and address any issues. Dr. Laudenslager encourages patients to discuss bone health with their medical providers proactively, especially those taking obesity medications. Seeking care from qualified professionals can provide additional guidance tailored to individual needs.

Conclusion

GLP-1 medications are transforming treatment for obesity and related conditions, but ongoing research is essential to understand their broader implications, including effects on bone health. By staying informed and incorporating protective measures, patients can better manage their health outcomes. Despite the societal stigma surrounding obesity treatments, Dr. Laudenslager reassures patients that the side effects of GLP-1s are manageable with proficient medical oversight.